Citation & Authors
Front Immunol. 2026;17:1867117.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
Preface
The global prevalence of rheumatoid arthritis (RA) is increasing, and some glucose-lowering drugs have been reported to reduce its risk. This multicenter target trial emulation compared incident RA risk in patients with type 2 diabetes receiving SGLT2 inhibitors or other treatments.
method
TriNetX identified 4,991,988 patients with type 2 diabetes between January 1, 2016, and June 30, 2023. Separate propensity score-matched comparisons yielded 310,507 pairs for SGLT2 inhibitors versus sulfonylureas, 206,069 pairs versus DPP-4 inhibitors, and 80,846 pairs versus pioglitazone. Kaplan–Meier methods assessed the relative risk of RA across groups. Subgroup analyses considered sex, age, race, obesity, HbA1c, and eGFR, and an additional intention-to-treat sensitivity analysis was conducted.
result
Compared with sulfonylureas, SGLT2 inhibitors were significantly associated with a lower risk of incident RA (HR 0.899; 95% CI 0.835–0.968). Comparisons with DPP-4 inhibitors (0.914; 0.831–1.005) and pioglitazone (0.922; 0.796–1.068) were not significant. Kaplan–Meier curves also showed fewer RA events with SGLT2 inhibitors than with sulfonylureas (log-rank p=0.004). Results were consistent across analyzed subgroups, and sensitivity analyses supported the robustness of this comparison.
discuss
In patients with type 2 diabetes, SGLT2 inhibitors were associated with a lower risk of incident RA than sulfonylureas. Given the observational design, however, the findings should be interpreted as associations rather than causal evidence.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
